Modification of serum IGF-I, IGFBPS and SHBG levels by different HRT regimens

Maturitas

Volumn 45, Issue 4, 2003, Pages 283-291

  Biglia, Nicoletta ^a   Ambroggio, Simona ^a   Ponzone, Riccardo ^a   Sgro, Luca ^a   Ujcic, Ester ^a   Dato, Fabrizia Actis ^a   Sismondi, Piero ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Hormone replacement therapy (HRT); IGF I; IGFBPs; SHBG

Indexed keywords

CYPROTERONE; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; NORETHISTERONE ACETATE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNOASSAY; MENOPAUSAL SYNDROME; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

NETA;

EID: 0041631025     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(03)00156-7     Document Type: Article

References (57)

1. Iranmanesh A., Veldhuis J.D. Clinical pathophysiology of the somatotropic (GH) axis in adult. Neuroendocrinology. 21:1992;783.
2. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16:1995;3.
3. Krywicki R.F., Yee D. The insulin-like growth factor family of ligands, receptors, and binding proteins. Breast Cancer Res. Treat. 22:1992;7.
4. Shimasaki S., Shimonaka M., Zhang H.P., Ling N. Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. J. Biol. Chem. 266:1991;10646.
5. Shimasaki S., Gao L., Shimonaka M., Ling N. Isolation and molecular cloning of insulin-like growth factor binding protein-6. Mol. Endocrinol. 5:1991;938.
6. Westley B.R., May F.E.B. Role of insulin-like growth factors in steroid modulated proliferation. J. Steroid Biochem. Mol. Biol. 51:1994;1.
7. Yu H., Spitz M.R., Mistry J., et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: a cause control analysis. J. Natl. Cancer Inst. 91:1999;151.
8. Ma J., Pollak M.N., Giovanucci E., et al. Prospecive study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 91:1999;620.
9. Djavan B., Bursa B., Seitz C., et al. Insulin-like growth factor-I (IGF-I), IGF-I density and IGF-I/PSA ratio for prostate cancer detection. Urology. 54:1999;603.
10. Cullen K.J., Allison A., Martire I., et al. Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res. Treat. 22:1992;21.
11. Lipworth L., Adami H.-O., Trichopoulos D., et al. Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Epiodemiology. 1:1996;96.
12. Peyrat J.P., Bonneterre J., Hecquet B., et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur. J. Cancer. 4:1993;492.
13. Bruning P.F., Van Doorn J., Bonfrer J.M.G., Van Noord P.A.H., et al. Insulin-like growth factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int. J. Cancer. 62:1995;266.
14. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351:1998;1393.
15. Kaaks R., Lundin E., Rinaldi S., et al. Prospective study of IGF-I, IGF binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control. 13:2002;307-316.
16. Vadgama J.V., Wu Y., Datta G., et al. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology. 57:1999;330.
17. Byrne C., Colditz G.A., Willett W.C., et al. Plasma Insulin-like Growth Factor (IGF) I, IGF-binding Protein-3, and mammographic density. Cancer Res. 60:2000;3744.
18. Siiteri P.K., Hammond G.L., Nisker J.A. Increased availability of serum estrogens in breast cancer: a new hypothesis. Pike M.C., Siiteri P.K., Welsh C.W. Banbury report 8. Hormones and breast cancer. 1981;87 Cold Spring Harbor Laboratory, New York.
19. Reed M.J., Cheng R.W., Noel C.T., et al. Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res. 43:1983;3940.
20. Moore J.W., Clark G.M.G., Bulbrook R.D., et al. Serum concentrations of total and non-protein-bound oestradiol in patients with breast cancer and in normal controls. Int. J. Cancer. 29:1982;17.
21. Jones L.A., Ota D.M., Gilchrist A.J., et al. Bioavailability of estradiol as a marker for breast cancer risk assessment. Cancer Res. 47:1987;5224.
22. Stomati M., Hartmann B., Spinetti A., et al. Effects of hormone replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-I levels in postmenopausal women. J. Endocrinol. Invest. 19:1996;535.
23. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 350:1997;1047-1059.
24. Nelson H.D., Humphrey L.L., Nygren P., et al. Postmenopausal hormone replacement therapy: scientific review. J. Am. Med. Assoc. 288:2002;872-881.
25. Bergkvist L., Adami H.O., Persson I., et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. New Engl. J. Med. 321:1989;293.
26. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int. J. Cancer. 42:1988;832.
27. Magnusson C., Baron J.A., Correia N., et al. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int. J. Cancer. 81:(3):1999;339.
28. Stanford J.L., Weiss N.S., Voigt L.F., et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. J. Am. Med. Assoc. 274:(2):1995;137.
29. Newcomb P.A., Longnecker M.P., Storer B.E., et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am. J. Epidemiol. 142:(8):1995;788.
30. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogens versus estrogen plus progestin. J. Natl. Cancer Inst. 92:2000;328-332.
31. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J. Am. Med. Assoc. 283:2000;485-491.
32. Campagnoli C., Biglia N., Cantamessa C., et al. Effects of progestins on IGF-I serum level in estrogen-treated postmenopausal women. Zentralbl. Gynakol. 119:1997;7.
33. Dawson-Hughes B., Stern D., Goldman J., Reichlin S. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effects of physiological estrogen replacement. J. Clin. Endocrinol. Metab. 63:1986;424.
34. Weissberger A.J., Ho K.K.Y., Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-h growth hormone (GH) secretion, insulin-like growth factor-I, and GH-binding protein in postmenopausal women. J. Clin. Endocrinol. Metab. 72:1991;374.
35. Kelly J.J., Rajkovic I.A., O'Sullivan A.J., et al. Effects of different oral estrogen formulation on insulin-like growth factor-I, growth hormone and growth hormone binding protein in postmenopausal women. Clin. Endocrinol. 39:1993;561.
36. Hartmann B., Kirchengast S., Albrecth A., et al. Effects of hormone replacement therapy on growth hormone secretion patterns in correlation to somatometric parameters in healthy postmenopausal women. Maturitas. 22:1995;239.
37. Campagnoli C., Biglia N., Altare F., et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol. Endocrinol. 7:1993;251.
38. Campagnoli C., Biglia N., Peris C., Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol. Endocrinol. 9:1995;67.
39. Goodman-Gruen D., Barrett-Connor E. Effect of replacement estrogen on insulin-like growth factor-I in postmenopausal women: the Rancho Bernardo study. J. Clin. Endocrinol. Metab. 81:1996;4268.
40. Kam G.Y.W., Leung K.C., Baxter R.C., Ho K.K.Y. Estrogen exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J. Clin. Endocrinol. Metab. 85:2000;1918.
41. Cardim H.J.P., Carvalho Lopes C.M., Giannella-Neto D., et al. The insulin-like growth factor-I system and hormone replacement therapy. Fertil. Steril. 75:2001;282.
42. Heald A., Selby P.L., White A., Gibson J.M. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Am. J. Obstet. Gynecol. 183:2000;593.
43. Paassilta M., Karjalainen A., Kervinen K., et al. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. Atherosclerosis. 149:2000;157-162.
44. Cano A., Castelo-Branco C., Tarin J.J. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Fertil. Steril. 71:1999;261-267.
45. Raudaskoski T., Knip M., Laatikainen T. Plasma insulin-like growth factor-I and its binding proteins-1 and -3 during continuous non oral and oral combined hormone replacement therapy. Menopause. 5:1998;217-222.
46. Helle S.I., Omsjo I.H., Hughes S.C., et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins-1 and -3: a cross-over study. Clin. Endocrinol. 45:1996;727-732.
47. Campagnoli C., Colombo P., De Aloysio D., et al. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. Maturitas. 41:2002;299-311.
48. Karjalainen A., Paassilta M., Heikkinen J., et al. Effects of peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism. Clin. Endocrinol. 54:2001;165-173.
49. Giudice L.C., Farrel E.M., Pham H., et al. Insulin like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effect of a pregnancy-associated serum protease activity. J. Clin. Endocrinol. Metab. 71:1990;806.
50. Frost V.J., Macaulay M., Wass J.A.H., et al. Proteolytic modification of insulin-like growth factor binding proteins: comparison of conditioned media from human cell lines, circulating proteases and characterized enzymes. J. Endocrinol. 138:1993;545.
51. Frost V.J., Helle S.I., Lonning P.E., et al. Effects of treatment with megestrole acetate, aminoglutethimide, or fomestane on Insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J. Clin. Endocrinol. Metab. 81:1996;2216.
52. Oh Y. IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res. Treat. 47:1998;283.
53. Toniolo P., Bruning P.F., Akhmedkhanov A., et al. Serum insulin-like growth factor-I and breast cancer risk. Int. J. Cancer. 88:2000;828.
54. Bruning P.F., Van Doorn J., Bonfrer J.M.G., et al. Insulin-like growth factor binding protein-3 is decreased in early stage operable premenopausal breast cancer. Int. J. Cancer. 62:1995;266.
55. Peyrat J.P., Bonneterre J., Hecquet B., et al. Plasma insulin-like growth factor-I (IGF-I) concentrations in human breast cancer. Eur. J. Cancer. 29A:1993;492.
56. Zhang X., Yee D. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res. 62:2002;4369.
57. Goodwin P.J., Ennis M., Pritcchard K.I., et al. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res. Treat. 74:2002;65.